Global Antibodies Market Overview: More than US$ 1,000 Mn worth Primary Antibodies is Estimated to be Sold Worldwide by 2022.

The global demand for antibodies is expected to remain moderate in the forthcoming years. Increasing prevalence of chronic ailments such as autoimmune diseases, cancer, diabetes and others is encouraging manufacturers to step up investments in R&D activities pertaining to antibodies. In addition, frequent outbreak of infectious diseases in various parts of the world coupled with growing popularity of protein therapeutics, is driving the sales of antibodies drugs. Sales of antibody-based medicines is expected to remain steady in developed regions such as Europe and North America. At the same time, introduction of alternative therapeutic drugs is projected to impact the growth of the global antibodies market. Moreover, factors such as risk of side effects related with antibodies and high-cost remain the major growth deterrents of the market. According to the latest report published by Fact.MR, the global antibodies market is expected to surpass a valuation of US$ 3,000 Mn by end of 2022, reflecting a steady CAGR between 2017 and 2022.

Request for Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=194

Forecast Highlights on Global Market for Antibodies

1- In terms of revenue, North America currently holds the predominant share of the global market for antibodies and the region is expected to retain its top position over 2022. Further, the North America’s market is anticipated to expand at steady CAGR between 2017 and 2022. This is primarily owing to the existence of an advanced healthcare infrastructure and prominent market participants in the region.

2- Based on product type, demand for primary antibodies is significantly high. Global sales of primary antibodies currently account for the largest revenue share of the market. More than US$ 1,000 Mn worth primary antibodies is estimated to be sold worldwide by the end of the forecast period.

3- On the basis of end user, the academic & research institutes segment is expected to remain highly attractive throughout the assessment period. In terms of revenue, the segment currently commands for more than one-third share of the global market. Towards the end of 2022, this segment is anticipated surpass a valuation of US$ 1,286 Mn, registering a steady growth.

4- On the basis of application, the basic research segment currently hold the top position. In addition, the basic research segment is estimated to command for a significant revenue share of the market in 2017 and beyond. By the end of 2022, the segment is expected to cross a market valuation of US$ 1,741 Mn, representing a CAGR of over 3%. Antibodies are used for various research purposes, especially for diagnostics and development of new drugs. Using antibodies drug developers determine the resistance level of various indigents.

Browse Full Report with TOC- https://www.factmr.com/report/194/antibodies-market

North America at the Forefront of the Global Antibodies Market
Currently, North America dominates the global antibodies market in terms of revenue and trend is projected continue in 2017 and beyond. In addition, the market in the region is expected to increase at a moderate CAGR during the forecast period (2017-2022). Presence of leading market players and existence of a well-established healthcare infrastructure is supporting the growth of the market in the region.

Primary Antibodies to Remain Top Selling Product Type
On the basis of product type, the primary antibodies segment currently accounts for the highest share of the global antibodies market in terms of revenue. Towards the end of forecast period, the segment is expected to reach a valuation in excess of US$ 1,091 Mn, reflecting a steady CAGR. The primary antibodies segment is projected to create an absolute $ opportunity of US$ 168.4 Mn between 2017 and 2022.

Competition Tracking
The report has also profiled key players operating in the global antibodies market, which include Abcam Plc, A.M.S. Biotechnology (Europe) Limited, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Genscript Biotech Corporation, Sigma Aldrich Corp, Crown Bioscience, Inc., Thermo Fisher Scientific, Inc.

Check Discount on this Report- https://www.factmr.com/connectus/sample?flag=D&rep_id=194

About Fact.MR
Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.